Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/acr.21809 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elimination of oral foci of infection might lead to clinical improvement of Graves' orbitopathy.
Graefes Arch Clin Exp Ophthalmol
January 2025
Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland.
Purpose: Graves' disease (GD) and Graves' orbitopathy (GO) are multifactorial disorders with links to the gut microbiome and autoimmunity. It is observed that patients with GD exhibit altered gut microbiome diversity. However, little is known about the role of oral microbiota in GD and GO.
View Article and Find Full Text PDFTopical Steroid Withdrawal in Atopic Dermatitis: Patient-reported Characterization from a Swedish Social Media Questionnaire.
Acta Derm Venereol
January 2025
Department of Public Health and Clinical Medicine, Dermatology and Venereology, Umeå University, Umeå, Sweden.
Topical steroid withdrawal (TSW) is described as an adverse reaction to topical glucocorticoids (TGCs). A pathophysiological mechanism has not been identified. There are no diagnostic criteria.
View Article and Find Full Text PDFZanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.
Cancer
January 2025
Department of Lymphoma, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Background: Double-expressor lymphoma (DEL) has a poorer prognosis than other subtypes of diffuse large B-cell lymphoma (DLBCL). This study is a multicenter, prospective, single-arm, phase 2 clinical study initiated by investigators to evaluate the efficacy and safety of combined zanubrutinib with R-CHOP, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone for patients with DEL (stage II or more), as well as to explore factors related to efficacy preliminarily.
Methods: From November 2020 to July 2022, 48 newly diagnosed patients were enrolled.
Cerebral venous thrombosis as a rare complication of Sjögren's syndrome: case series and literature review.
Clin Rheumatol
January 2025
Department of Rheumatology & Allergy, Xuanwu Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- This study examines a rare complication of cerebral venous thrombosis (CVT) in patients with primary Sjögren's syndrome (pSS), discussing clinical features, treatment, and outcomes.
- A total of twelve patients were reviewed, predominantly middle-aged women, with common symptoms including headache and typical pSS manifestations such as dry mouth and arthritis.
- All patients received treatment including anticoagulants and recovered fully, highlighting the need for increased awareness and screening for autoimmune diseases in CVT cases, especially with unilateral transverse sinus involvement.
Application of Nanomaterials Targeting Immune Cells in the Treatment of Chronic Inflammation.
Int J Nanomedicine
December 2024
Department of Oral Implantology, Hospital of Stomatology, Jilin University, Changchun, 130021, People's Republic of China.
Article Synopsis
- Chronic inflammation is linked to various diseases and is characterized by prolonged immune cell activation, resulting in tissue damage.
- Despite the effectiveness of current anti-inflammatory medications, they often have side effects due to non-specific targeting.
- Nanoparticle drug delivery shows promise for targeted therapy in inflammation, but improvements are needed to specifically target different immune cell types for enhanced therapeutic effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!